BofA raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $230 from $225 and keeps a Buy rating on the shares. Based on Q3 pricing and volume trends for key drugs as well as relevant company commentary, the firm previewed Q3 EPS updates for its commercial-stage biopharma coverage, telling investors that it does not expect any major Q3 beats/misses and no big 2026 revisions among the group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals announces FDA approves Zepzelca in ES-SCLC
- FDA approves combo of Jazz’s lurbinectedin and Roche’s atezolizumab for ES-SCLC
- Crane NXT appoints Kim DiMaurizio as SVP, CPO
- Why Are Cannabis Stocks Up Today?
- Jazz Pharmaceuticals price target raised to $167 from $163 at Morgan Stanley